Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.
Throughout September 2021 we tracked the global conversations of 3774 HCPs who posted 6119 English-language Twitter posts about the launches and approvals of new products.
After the significant spike in conversation amongst HCPs last month due to the FDA approval of Pfizer’s COVID-19 vaccine, conversation levels in September had returned to their usual levels. The product HCPs were most vocal about this month continued to be the Pfizer vaccine, as they advocated for the uptake of the vaccine following its full FDA approval last month and discussed the decision around the approval of the booster shot for those over 65, but not for all those over 16. Alongside this discussion, HCPs also made positive comments on the FDA’s approval of Takeda’s Exkivity (mobocertinib) treatment, as well as Merck’s Keytruda (pembrolizumab).
Within the discussion around the FDA’s Pfizer vaccines approval, HCPs amplified the President’s call for the public to get vaccinated now that the Pfizer COVID-19 vaccine after its full approval last month, retweeting it 162 times. They also drew attention to James Surowiecki’s tweet noting that Regeneron’s antibody cocktail for COVID-19 had not yet reached FDA approval, whilst the vaccine was fully approved.
Antivaxxers' affection for Regeneron is fascinating. It's under an EUA, and is not FDA-approved. It's a new technology. Its clinical trials started just before the trials for the vaxxes, so we have no idea what the long-term effects of taking it are. And yet antivaxxers love it.
— James Surowiecki (@JamesSurowiecki) September 17, 2021
My message to unvaccinated Americans is this: What more is there to wait for? What more do you need to see?
We have made the vaccinations free, safe, and convenient. The vaccine has FDA approval. Over 200 million Americans have gotten at least one shot.
Do the right thing.
— President Biden (@POTUS) September 10, 2021
Many other HCPs also added their own voice to this discussion, supporting the use of the Pfizer COVID-19 vaccine ahead of the Rengeron treatment.
To be clear, the Regeneron monoclonal antibody cocktail is not fully approved by the FDA, due to a lack of data for full approval. The Pfizer vaccine is fully approved for COVID.
— Defund Politics – Campaign Finance Reform (@jsdpharmd) September 18, 2021
So the same people who refused to get the FDA approved vaccine to prevent Covid because they don’t trust science, are demanding to be treated with the the non FDA approved, “emergency use only” Regeneron cocktail, after they get Covid.
— Shari Lynn (@LynnSharig8) September 16, 2021
Though the level of HCP engagement around the FDA approvals of Takeda’s (mobocertinib) was lower than that around the Pfizer vaccine, those who commented spoke positively about the drug. Exkivity was heralded as a great step forward for patients with (EGFR) Exon 20 Insertion and non-small cell lung cancers (NSCLC) and HCPs were impressed with the innovation.
Mobocertinib (TAK-788) granted FDA approval for patients with EGFR Exon 20 mutations who have received prior platinum-based chemotherapy. Nice to have an oral treatment option for this disease! https://t.co/jFpNV9jDfE
— Ryan Gentzler, MD (@ryangentzler) September 16, 2021
— Mark Awad (@DrMarkAwad) September 15, 2021
The three most shared links from HCPs discussing product launches in June were:
- An FDA article about Why you should not use ivermectin to treat or prevent COVID-19.
- A Takeda article about The FDA approval of EXKIVITY™ (mobocertinib) as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion + NSCLC
- A Healio article about The FDA granting breakthrough therapy designation to empagliflozin for HFpEF
Each month, CREATION.co tracks the HCP conversation relating to new product launches.
You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
- Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 June and 30 June 2021 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
- Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
- Between 01 June and 30 June 2021, there were 5,596 HCP mentions of new pharmaceutical product launches and drug approvals from 3,471 unique HCP authors from around the world.